Issue 10 | December 2023

Welcome to the final Seuss+ Newsletter of the year

Take a trip back through 2023 with us, and dive into the knowledge we shared throughout the year and the news and views that continue to ripple through the industry. Catch up on any Cut the Chat podcast episodes you missed to finish the year feeling inspired.

Happy Holidays – We’ll be Back January 2nd!

The days are short and the fairy lights are twinkling… that can mean only one thing: Happy Holidays from all of us at Seuss+! However you’re planning to see out 2023 and welcome the New Year, we hope you have time to reflect and relax. We’ll be taking a break too, so the Seuss+ office will be closed from December 27th to January 1st. See you in 2024!

Interesting Reads

2023: A Year of Collaboration and Knowledge Sharing for Seuss+

With podcast episodes, webinars, free email courses and a multitude of different clients, we have been busy in 2023 sharing our expertise and experience to solve complex business challenges and support biotech and pharma companies as they transform patients’ lives. In this roundup of 2023, Seuss+ Marketing Director Gina Dunn looks back over 12 months of collaboration and knowledge sharing. Read more >

Let’s Cut the Chat and Catch Up

In our podcast Cut the Chat, Seuss+ Co-Founders and CEOs Sabine Hutchison and Kieran Canisius get straight to the point with expert guests from across the industry. This year they’ve covered topics like successful collaborations in biotech, diversity strategies, creativity, and measuring what matters. Missed an episode? You can catch up on them all here! Listen now >

Protocol amendments are common and highly inefficient, could AI turn the tide?

Sponsors are familiar with the pain of amending a study protocol – something that happens in about 80% of all late-stage phase III protocols, according to a study by Tufts Center for the Study of Drug Development (Tufts CSDD). In fact, amendments have increased by 60% over the last seven years alone. Why? Because of the increasing complexity of clinical trials. The amendment process can be costly and often leads to reconsenting participants. Sponsors are resigned to the need for amendments, but they’re seeking ways to reduce the inefficiencies involved – including using AI. Read more >

Going to J.P. Morgan in San Francisco in January? Meet Seuss+!

Will you be attending the J.P. Morgan Healthcare Conference in January? Seuss+ CEOs and Co-Founders Sabine Hutchison and Kieran Canisius will be together in San Francisco, and they’d love to get together with you! Get in touch with us to schedule a meeting. Contact us >

Your Brand Matters Way More Than You Think in Life Sciences

Discover the key role of branding in life sciences in our insightful blog. Learn how a strong brand strategy extends beyond logos to embody your company’s identity, values, and mission in this industry. Gain insights into effective branding for biotech, CROs, and B2B tech companies to align your brand with commercial goals for tangible results. Read more >

About Seuss+

Seuss+ is a collaborative and trusted international life science consultancy. We creatively solve complex business challenges so our clients can focus on what they do best—science. We support drug development program success and organizational growth through our unique partner approach and portfolio of tailored and strategic business solutions.